Medicis announces FDA OK of broader indication for Vanos cream

By Elaine Rigoli

Tampa, Fla., March 2 - Medicis Pharmaceutical Corp. announced Thursday that the Food and Drug Administration has broadened the indication of Vanos, a class 1 corticosteroid launched in April 2005 and originally indicated for the treatment of plaque-type psoriasis.

Vanos is now indicated as a primary therapy for all inflammatory and pruritic skin conditions in patients 12 years of age or older who are responsive to corticosteroids, according to a company news release.

Vanos is a high-potency cream for once or twice daily application for patients with psoriasis and once daily in other indicated conditions.

Vanos is patent-protected until 2021.

The drug is available by prescription in a 30-gram size and a 60-gram size. The most common adverse events associated with the use of Vanos are headache and burning at the application site, the release said.

Vanos is manufactured by Patheon, Inc. in Canada.

Scottsdale, Ariz.-based Medicis is a specialty pharmaceutical company focusing primarily on the treatment of dermatological and podiatric conditions and aesthetics medicine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.